Nuvation Bio NUVB R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's r&d credit carryforward?
- Nuvation Bio (NUVB) reported r&d credit carryforward of $23.38M in Q4 2025.
- How has Nuvation Bio's r&d credit carryforward changed year-over-year?
- Nuvation Bio's r&d credit carryforward increased by 20.6% year-over-year, from $19.38M to $23.38M.
- What is the long-term trend for Nuvation Bio's r&d credit carryforward?
- Over 5 years (2020 to 2025), Nuvation Bio's r&d credit carryforward has grown at a 101.8% compound annual growth rate (CAGR), from $698K to $23.38M.
- What does r&d credit carryforward mean?
- This represents the value of tax credits generated from research and development activities that can be applied to reduce future tax liabilities. For clinical-stage companies, these assets are vital as they represent potential future cash flow savings once the company becomes profitable. A larger carryforward balance indicates a significant historical investment in innovation that provides a future tax shield.